Topics
Oligodendroglioma | Treatment | Chemotherapy
Home > Publications > Topics > Oligodendroglioma > Treatment > Chemotherapy
Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C,
Bronnimann C, Vauleon E, Djelad A, Cohen-Jonathan Moyal E,
Langlois O, Campone M, Ducloie M, Noel G, Cuzzubbo S, Taillandier
L, Ramirez C, Younan N, Menei P, Dhermain F, Desenclos C,
Ghiringhelli F, Bourg V, Ricard D, Faillot T, Appay R, Tabouret E,
Nichelli L, Mathon B, Thomas A, Tran S, Bielle F, Alentorn A,
Iorgulescu JB, Boëlle PY, Labreche K, Hoang-Xuan K, Sanson M,
Idbaih A, Figarella-Branger D, Ducray F, Touat M; POLA Network.
Survival Outcomes Associated With
First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in
Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade
3 Oligodendroglioma.
J
Clin Oncol. 2024 Oct 2:JCO2400049. doi:
10.1200/JCO.24.00049. PMID:
39356975. Observational study˰
ˍ
*Rincon-Torroella J, Rakovec M, Kalluri AL, Jiang K, Weber-Levine
C, Parker M, Raj D, Materi J, Sepehri S, Ferres A, Schreck KC,
Aldecoa I, Lucas CG, Sair HI, Redmond KJ, Holdhoff M, Weingart J,
Brem H, Sánchez JJG, Ye X, Bettegowda C.
Impact
of upfront adjuvant chemoradiation on survival in patients with
molecularly defined
oligodendroglioma: the benefits of PCV over TMZ.
J
Neurooncol. 2024 Oct 9.
doi:
10.1007/s11060-024-04829-6. PMID:
39382617. Observational study˰
ˍ